Table of Content

1 Myasthenia Gravis Drugs Market Overview
1.1 Myasthenia Gravis Drugs Product Scope
1.2 Myasthenia Gravis Drugs Segment by Type
1.2.1 Global Myasthenia Gravis Drugs Sales by Type (2016 & 2021 & 2027)
1.2.2 Anticholinesterases
1.2.3 Immunosuppressants
1.2.4 Intravenous Immune Globulins
1.3 Myasthenia Gravis Drugs Segment by Application
1.3.1 Global Myasthenia Gravis Drugs Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Myasthenia Gravis Drugs Market Estimates and Forecasts (2016-2027)
1.4.1 Global Myasthenia Gravis Drugs Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Myasthenia Gravis Drugs Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Myasthenia Gravis Drugs Price Trends (2016-2027)

2 Myasthenia Gravis Drugs Estimates and Forecasts by Region
2.1 Global Myasthenia Gravis Drugs Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Myasthenia Gravis Drugs Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Myasthenia Gravis Drugs Sales Market Share by Region (2016-2021)
2.2.2 Global Myasthenia Gravis Drugs Revenue Market Share by Region (2016-2021)
2.3 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Myasthenia Gravis Drugs Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Myasthenia Gravis Drugs Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Myasthenia Gravis Drugs Estimates and Projections (2016-2027)
2.4.2 Europe Myasthenia Gravis Drugs Estimates and Projections (2016-2027)
2.4.3 China Myasthenia Gravis Drugs Estimates and Projections (2016-2027)
2.4.4 Japan Myasthenia Gravis Drugs Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Myasthenia Gravis Drugs Estimates and Projections (2016-2027)
2.4.6 India Myasthenia Gravis Drugs Estimates and Projections (2016-2027)

3 Global Myasthenia Gravis Drugs Competition Landscape by Players
3.1 Global Top Myasthenia Gravis Drugs Players by Sales (2016-2021)
3.2 Global Top Myasthenia Gravis Drugs Players by Revenue (2016-2021)
3.3 Global Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2020)
3.4 Global Myasthenia Gravis Drugs Average Price by Company (2016-2021)
3.5 Manufacturers Myasthenia Gravis Drugs Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Myasthenia Gravis Drugs Market Size by Type
4.1 Global Myasthenia Gravis Drugs Historic Market Review by Type (2016-2021)
4.1.1 Global Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
4.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2016-2021)
4.1.3 Global Myasthenia Gravis Drugs Price by Type (2016-2021)
4.2 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Global Myasthenia Gravis Drugs Price Forecast by Type (2022-2027)

5 Global Myasthenia Gravis Drugs Market Size by Application
5.1 Global Myasthenia Gravis Drugs Historic Market Review by Application (2016-2021)
5.1.1 Global Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
5.1.2 Global Myasthenia Gravis Drugs Revenue Market Share by Application (2016-2021)
5.1.3 Global Myasthenia Gravis Drugs Price by Application (2016-2021)
5.2 Global Myasthenia Gravis Drugs Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Myasthenia Gravis Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Myasthenia Gravis Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Myasthenia Gravis Drugs Price Forecast by Application (2022-2027)

6 North America Myasthenia Gravis Drugs Market Facts & Figures
6.1 North America Myasthenia Gravis Drugs Sales by Company
6.1.1 North America Myasthenia Gravis Drugs Sales by Company (2016-2021)
6.1.2 North America Myasthenia Gravis Drugs Revenue by Company (2016-2021)
6.2 North America Myasthenia Gravis Drugs Sales Breakdown by Type
6.2.1 North America Myasthenia Gravis Drugs Sales Breakdown by Type (2016-2021)
6.2.2 North America Myasthenia Gravis Drugs Sales Breakdown by Type (2022-2027)
6.3 North America Myasthenia Gravis Drugs Sales Breakdown by Application
6.3.1 North America Myasthenia Gravis Drugs Sales Breakdown by Application (2016-2021)
6.3.2 North America Myasthenia Gravis Drugs Sales Breakdown by Application (2022-2027)

7 Europe Myasthenia Gravis Drugs Market Facts & Figures
7.1 Europe Myasthenia Gravis Drugs Sales by Company
7.1.1 Europe Myasthenia Gravis Drugs Sales by Company (2016-2021)
7.1.2 Europe Myasthenia Gravis Drugs Revenue by Company (2016-2021)
7.2 Europe Myasthenia Gravis Drugs Sales Breakdown by Type
7.2.1 Europe Myasthenia Gravis Drugs Sales Breakdown by Type (2016-2021)
7.2.2 Europe Myasthenia Gravis Drugs Sales Breakdown by Type (2022-2027)
7.3 Europe Myasthenia Gravis Drugs Sales Breakdown by Application
7.3.1 Europe 138 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 138 Sales Breakdown by Application (2022-2027)

8 China Myasthenia Gravis Drugs Market Facts & Figures
8.1 China Myasthenia Gravis Drugs Sales by Company
8.1.1 China Myasthenia Gravis Drugs Sales by Company (2016-2021)
8.1.2 China Myasthenia Gravis Drugs Revenue by Company (2016-2021)
8.2 China Myasthenia Gravis Drugs Sales Breakdown by Type
8.2.1 China Myasthenia Gravis Drugs Sales Breakdown by Type (2016-2021)
8.2.2 China Myasthenia Gravis Drugs Sales Breakdown by Type (2022-2027)
8.3 China Myasthenia Gravis Drugs Sales Breakdown by Application
8.3.1 China 166 Sales Breakdown by Application (2016-2021)
8.3.2 China 166 Sales Breakdown by Application (2022-2027)

9 Japan Myasthenia Gravis Drugs Market Facts & Figures
9.1 Japan Myasthenia Gravis Drugs Sales by Company
9.1.1 Japan Myasthenia Gravis Drugs Sales by Company (2016-2021)
9.1.2 Japan Myasthenia Gravis Drugs Revenue by Company (2016-2021)
9.2 Japan Myasthenia Gravis Drugs Sales Breakdown by Type
9.2.1 Japan Myasthenia Gravis Drugs Sales Breakdown by Type (2016-2021)
9.2.2 Japan Myasthenia Gravis Drugs Sales Breakdown by Type (2022-2027)
9.3 Japan Myasthenia Gravis Drugs Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Myasthenia Gravis Drugs Market Facts & Figures
10.1 Southeast Asia Myasthenia Gravis Drugs Sales by Company
10.1.1 Southeast Asia Myasthenia Gravis Drugs Sales by Company (2016-2021)
10.1.2 Southeast Asia Myasthenia Gravis Drugs Revenue by Company (2016-2021)
10.2 Southeast Asia Myasthenia Gravis Drugs Sales Breakdown by Type
10.2.1 Southeast Asia Myasthenia Gravis Drugs Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Myasthenia Gravis Drugs Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Myasthenia Gravis Drugs Sales Breakdown by Application
10.3.1 Southeast Asia K MT Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K MT Sales Breakdown by Application (2022-2027)

11 India Myasthenia Gravis Drugs Market Facts & Figures
11.1 India Myasthenia Gravis Drugs Sales by Company
11.1.1 India Myasthenia Gravis Drugs Sales by Company (2016-2021)
11.1.2 India Myasthenia Gravis Drugs Revenue by Company (2016-2021)
11.2 India Myasthenia Gravis Drugs Sales Breakdown by Type
11.2.1 India Myasthenia Gravis Drugs Sales Breakdown by Type (2016-2021)
11.2.2 India Myasthenia Gravis Drugs Sales Breakdown by Type (2022-2027)
11.3 India Myasthenia Gravis Drugs Sales Breakdown by Application
11.3.1 India Myasthenia Gravis Drugs Sales Breakdown by Application (2016-2021)
11.3.2 India Myasthenia Gravis Drugs Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Myasthenia Gravis Drugs Business
12.1 Flamel Technologies
12.1.1 Flamel Technologies Corporation Information
12.1.2 Flamel Technologies Business Overview
12.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
12.1.5 Flamel Technologies Recent Development
12.2 F. Hoffmann-La Roche
12.2.1 F. Hoffmann-La Roche Corporation Information
12.2.2 F. Hoffmann-La Roche Business Overview
12.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products Offered
12.2.5 F. Hoffmann-La Roche Recent Development
12.3 Grifols
12.3.1 Grifols Corporation Information
12.3.2 Grifols Business Overview
12.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Grifols Myasthenia Gravis Drugs Products Offered
12.3.5 Grifols Recent Development
12.4 Pfizer
12.4.1 Pfizer Corporation Information
12.4.2 Pfizer Business Overview
12.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Pfizer Myasthenia Gravis Drugs Products Offered
12.4.5 Pfizer Recent Development
12.5 Takeda
12.5.1 Takeda Corporation Information
12.5.2 Takeda Business Overview
12.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Takeda Myasthenia Gravis Drugs Products Offered
12.5.5 Takeda Recent Development
12.6 Novartis
12.6.1 Novartis Corporation Information
12.6.2 Novartis Business Overview
12.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Novartis Myasthenia Gravis Drugs Products Offered
12.6.5 Novartis Recent Development
12.7 Bausch Health
12.7.1 Bausch Health Corporation Information
12.7.2 Bausch Health Business Overview
12.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Bausch Health Myasthenia Gravis Drugs Products Offered
12.7.5 Bausch Health Recent Development
12.8 Alexion Pharmaceuticals
12.8.1 Alexion Pharmaceuticals Corporation Information
12.8.2 Alexion Pharmaceuticals Business Overview
12.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products Offered
12.8.5 Alexion Pharmaceuticals Recent Development
12.9 Catalyst Pharmaceuticals
12.9.1 Catalyst Pharmaceuticals Corporation Information
12.9.2 Catalyst Pharmaceuticals Business Overview
12.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products Offered
12.9.5 Catalyst Pharmaceuticals Recent Development
12.10 CSL
12.10.1 CSL Corporation Information
12.10.2 CSL Business Overview
12.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 CSL Myasthenia Gravis Drugs Products Offered
12.10.5 CSL Recent Development
12.11 Curavac
12.11.1 Curavac Corporation Information
12.11.2 Curavac Business Overview
12.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Curavac Myasthenia Gravis Drugs Products Offered
12.11.5 Curavac Recent Development
12.12 Cytokinetics
12.12.1 Cytokinetics Corporation Information
12.12.2 Cytokinetics Business Overview
12.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Cytokinetics Myasthenia Gravis Drugs Products Offered
12.12.5 Cytokinetics Recent Development
12.13 Galencia
12.13.1 Galencia Corporation Information
12.13.2 Galencia Business Overview
12.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Galencia Myasthenia Gravis Drugs Products Offered
12.13.5 Galencia Recent Development
12.14 GlaxoSmithKline
12.14.1 GlaxoSmithKline Corporation Information
12.14.2 GlaxoSmithKline Business Overview
12.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Products Offered
12.14.5 GlaxoSmithKline Recent Development
12.15 Lupin Pharmaceuticals
12.15.1 Lupin Pharmaceuticals Corporation Information
12.15.2 Lupin Pharmaceuticals Business Overview
12.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Products Offered
12.15.5 Lupin Pharmaceuticals Recent Development
12.16 Mitsubishi Tanabe Pharma
12.16.1 Mitsubishi Tanabe Pharma Corporation Information
12.16.2 Mitsubishi Tanabe Pharma Business Overview
12.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Products Offered
12.16.5 Mitsubishi Tanabe Pharma Recent Development

13 Myasthenia Gravis Drugs Manufacturing Cost Analysis
13.1 Myasthenia Gravis Drugs Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Myasthenia Gravis Drugs
13.4 Myasthenia Gravis Drugs Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Myasthenia Gravis Drugs Distributors List
14.3 Myasthenia Gravis Drugs Customers

15 Market Dynamics
15.1 Myasthenia Gravis Drugs Market Trends
15.2 Myasthenia Gravis Drugs Drivers
15.3 Myasthenia Gravis Drugs Market Challenges
15.4 Myasthenia Gravis Drugs Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Myasthenia Gravis Drugs Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Myasthenia Gravis Drugs Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Myasthenia Gravis Drugs Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Myasthenia Gravis Drugs Sales (K MT) by Region (2016-2021)
Table 5. Global Myasthenia Gravis Drugs Sales Market Share by Region (2016-2021)
Table 6. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Myasthenia Gravis Drugs Revenue Share by Region (2016-2021)
Table 8. Global Myasthenia Gravis Drugs Sales (K MT) Forecast by Region (2022-2027)
Table 9. Global Myasthenia Gravis Drugs Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Myasthenia Gravis Drugs Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Myasthenia Gravis Drugs Revenue Share Forecast by Region (2022-2027)
Table 12. Global Myasthenia Gravis Drugs Sales (K MT) of Key Companies (2016-2021)
Table 13. Global Myasthenia Gravis Drugs Sales Share by Company (2016-2021)
Table 14. Global Myasthenia Gravis Drugs Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Myasthenia Gravis Drugs Revenue Share by Company (2016-2021)
Table 16. Global Myasthenia Gravis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Drugs as of 2020)
Table 17. Global Myasthenia Gravis Drugs Average Price (USD/MT) of Key Company (2016-2021)
Table 18. Manufacturers Myasthenia Gravis Drugs Manufacturing Sites and Area Served
Table 19. Manufacturers Myasthenia Gravis Drugs Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Myasthenia Gravis Drugs Sales (K MT) by Type (2016-2021)
Table 22. Global Myasthenia Gravis Drugs Sales Share by Type (2016-2021)
Table 23. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Myasthenia Gravis Drugs Price (USD/MT) by Type (2016-2021)
Table 25. Global Myasthenia Gravis Drugs Sales Share by Type (2022-2027)
Table 26. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Myasthenia Gravis Drugs Revenue Share by Type (2022-2027)
Table 28. Global Myasthenia Gravis Drugs Price (USD/MT) by Type (2022-2027)
Table 29. Global Myasthenia Gravis Drugs Sales (K MT) by Application (2016-2021)
Table 30. Global Myasthenia Gravis Drugs Sales Share by Application (2016-2021)
Table 31. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Myasthenia Gravis Drugs Price (USD/MT) by Application (2016-2021)
Table 33. Global Myasthenia Gravis Drugs Sales (K MT) by Application (2022-2027)
Table 34. Global Myasthenia Gravis Drugs Sales Share by Application (2022-2027)
Table 35. Global Myasthenia Gravis Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Myasthenia Gravis Drugs Revenue Share by Application (2022-2027)
Table 37. Global Myasthenia Gravis Drugs Price (USD/MT) by Application (2022-2027)
Table 38. North America Myasthenia Gravis Drugs Sales (K MT) by Company (2016-2021)
Table 39. North America Myasthenia Gravis Drugs Sales Market Share by Company (2016-2021)
Table 40. North America Myasthenia Gravis Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Myasthenia Gravis Drugs Revenue Market Share by Company (2016-2021)
Table 42. North America Myasthenia Gravis Drugs Sales by Type (2016-2021) & (K MT)
Table 43. North America Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
Table 44. North America Myasthenia Gravis Drugs Sales by Type (2022-2027) & (K MT)
Table 45. North America Myasthenia Gravis Drugs Sales Market Share by Type (2022-2027)
Table 46. North America Myasthenia Gravis Drugs Sales by Application (2016-2021) & (K MT)
Table 47. North America Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
Table 48. North America Myasthenia Gravis Drugs Sales by Application (2022-2027) & (K MT)
Table 49. North America Myasthenia Gravis Drugs Sales Market Share by Application (2022-2027)
Table 50. Europe Myasthenia Gravis Drugs Sales (K MT) by Company (2016-2021)
Table 51. Europe Myasthenia Gravis Drugs Sales Market Share by Company (2016-2021)
Table 52. Europe Myasthenia Gravis Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Myasthenia Gravis Drugs Revenue Market Share by Company (2016-2021)
Table 54. Europe Myasthenia Gravis Drugs Sales by Type (2016-2021) & (K MT)
Table 55. Europe Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
Table 56. Europe Myasthenia Gravis Drugs Sales by Type (2022-2027) & (K MT)
Table 57. Europe Myasthenia Gravis Drugs Sales Market Share by Type (2022-2027)
Table 58. Europe Myasthenia Gravis Drugs Sales by Application (2016-2021) & (K MT)
Table 59. Europe Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
Table 60. Europe Myasthenia Gravis Drugs Sales by Application (2022-2027) & (K MT)
Table 61. Europe Myasthenia Gravis Drugs Sales Market Share by Application (2022-2027)
Table 62. China Myasthenia Gravis Drugs Sales (K MT) by Company (2016-2021)
Table 63. China Myasthenia Gravis Drugs Sales Market Share by Company (2016-2021)
Table 64. China Myasthenia Gravis Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Myasthenia Gravis Drugs Revenue Market Share by Company (2016-2021)
Table 66. China Myasthenia Gravis Drugs Sales by Type (2016-2021) & (K MT)
Table 67. China Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
Table 68. China Myasthenia Gravis Drugs Sales by Type (2022-2027) & (K MT)
Table 69. China Myasthenia Gravis Drugs Sales Market Share by Type (2022-2027)
Table 70. China Myasthenia Gravis Drugs Sales by Application (2016-2021) & (K MT)
Table 71. China Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
Table 72. China Myasthenia Gravis Drugs Sales by Application (2022-2027) & (K MT)
Table 73. China Myasthenia Gravis Drugs Sales Market Share by Application (2022-2027)
Table 74. Japan Myasthenia Gravis Drugs Sales (K MT) by Company (2016-2021)
Table 75. Japan Myasthenia Gravis Drugs Sales Market Share by Company (2016-2021)
Table 76. Japan Myasthenia Gravis Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Myasthenia Gravis Drugs Revenue Market Share by Company (2016-2021)
Table 78. Japan Myasthenia Gravis Drugs Sales by Type (2016-2021) & (K MT)
Table 79. Japan Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
Table 80. Japan Myasthenia Gravis Drugs Sales by Type (2022-2027) & (K MT)
Table 81. Japan Myasthenia Gravis Drugs Sales Market Share by Type (2022-2027)
Table 82. Japan Myasthenia Gravis Drugs Sales by Application (2016-2021) & (K MT)
Table 83. Japan Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
Table 84. Japan Myasthenia Gravis Drugs Sales by Application (2022-2027) & (K MT)
Table 85. Japan Myasthenia Gravis Drugs Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Myasthenia Gravis Drugs Sales (K MT) by Company (2016-2021)
Table 87. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Myasthenia Gravis Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Myasthenia Gravis Drugs Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Myasthenia Gravis Drugs Sales by Type (2016-2021) & (K MT)
Table 91. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Myasthenia Gravis Drugs Sales by Type (2022-2027) & (K MT)
Table 93. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Myasthenia Gravis Drugs Sales by Application (2016-2021) & (K MT)
Table 95. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Myasthenia Gravis Drugs Sales by Application (2022-2027) & (K MT)
Table 97. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Application (2022-2027)
Table 98. India Myasthenia Gravis Drugs Sales (K MT) by Company (2016-2021)
Table 99. India Myasthenia Gravis Drugs Sales Market Share by Company (2016-2021)
Table 100. India Myasthenia Gravis Drugs Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Myasthenia Gravis Drugs Revenue Market Share by Company (2016-2021)
Table 102. India Myasthenia Gravis Drugs Sales by Type (2016-2021) & (K MT)
Table 103. India Myasthenia Gravis Drugs Sales Market Share by Type (2016-2021)
Table 104. India Myasthenia Gravis Drugs Sales by Type (2022-2027) & (K MT)
Table 105. India Myasthenia Gravis Drugs Sales Market Share by Type (2022-2027)
Table 106. India Myasthenia Gravis Drugs Sales by Application (2016-2021) & (K MT)
Table 107. India Myasthenia Gravis Drugs Sales Market Share by Application (2016-2021)
Table 108. India Myasthenia Gravis Drugs Sales by Application (2022-2027) & (K MT)
Table 109. India Myasthenia Gravis Drugs Sales Market Share by Application (2022-2027)
Table 110. Flamel Technologies Corporation Information
Table 111. Flamel Technologies Description and Business Overview
Table 112. Flamel Technologies Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 113. Flamel Technologies Myasthenia Gravis Drugs Product
Table 114. Flamel Technologies Recent Development
Table 115. F. Hoffmann-La Roche Corporation Information
Table 116. F. Hoffmann-La Roche Description and Business Overview
Table 117. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 118. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product
Table 119. F. Hoffmann-La Roche Recent Development
Table 120. Grifols Corporation Information
Table 121. Grifols Description and Business Overview
Table 122. Grifols Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 123. Grifols Myasthenia Gravis Drugs Product
Table 124. Grifols Recent Development
Table 125. Pfizer Corporation Information
Table 126. Pfizer Description and Business Overview
Table 127. Pfizer Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 128. Pfizer Myasthenia Gravis Drugs Product
Table 129. Pfizer Recent Development
Table 130. Takeda Corporation Information
Table 131. Takeda Description and Business Overview
Table 132. Takeda Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 133. Takeda Myasthenia Gravis Drugs Product
Table 134. Takeda Recent Development
Table 135. Novartis Corporation Information
Table 136. Novartis Description and Business Overview
Table 137. Novartis Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 138. Novartis Myasthenia Gravis Drugs Product
Table 139. Novartis Recent Development
Table 140. Bausch Health Corporation Information
Table 141. Bausch Health Description and Business Overview
Table 142. Bausch Health Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 143. Bausch Health Myasthenia Gravis Drugs Product
Table 144. Bausch Health Recent Development
Table 145. Alexion Pharmaceuticals Corporation Information
Table 146. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 147. Alexion Pharmaceuticals Description and Business Overview
Table 148. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product
Table 149. Alexion Pharmaceuticals Recent Development
Table 150. Catalyst Pharmaceuticals Corporation Information
Table 151. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 152. Catalyst Pharmaceuticals Description and Business Overview
Table 153. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product
Table 154. Catalyst Pharmaceuticals Recent Development
Table 155. CSL Corporation Information
Table 156. CSL Description and Business Overview
Table 157. CSL Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 158. CSL Myasthenia Gravis Drugs Product
Table 159. CSL Recent Development
Table 160. Curavac Corporation Information
Table 161. Curavac Description and Business Overview
Table 162. Curavac Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 163. Curavac Myasthenia Gravis Drugs Product
Table 164. Curavac Recent Development
Table 165. Cytokinetics Corporation Information
Table 166. Cytokinetics Description and Business Overview
Table 167. Cytokinetics Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 168. Cytokinetics Myasthenia Gravis Drugs Product
Table 169. Cytokinetics Recent Development
Table 170. Galencia Corporation Information
Table 171. Galencia Description and Business Overview
Table 172. Galencia Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 173. Galencia Myasthenia Gravis Drugs Product
Table 174. Galencia Recent Development
Table 175. GlaxoSmithKline Corporation Information
Table 176. GlaxoSmithKline Description and Business Overview
Table 177. GlaxoSmithKline Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 178. GlaxoSmithKline Myasthenia Gravis Drugs Product
Table 179. GlaxoSmithKline Recent Development
Table 180. Lupin Pharmaceuticals Corporation Information
Table 181. Lupin Pharmaceuticals Description and Business Overview
Table 182. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 183. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product
Table 184. Lupin Pharmaceuticals Recent Development
Table 185. Mitsubishi Tanabe Pharma Corporation Information
Table 186. Mitsubishi Tanabe Pharma Description and Business Overview
Table 187. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2016-2021)
Table 188. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product
Table 189. Mitsubishi Tanabe Pharma Recent Development
Table 190. Production Base and Market Concentration Rate of Raw Material
Table 191. Key Suppliers of Raw Materials
Table 192. Myasthenia Gravis Drugs Distributors List
Table 193. Myasthenia Gravis Drugs Customers List
Table 194. Myasthenia Gravis Drugs Market Trends
Table 195. Myasthenia Gravis Drugs Market Drivers
Table 196. Myasthenia Gravis Drugs Market Challenges
Table 197. Myasthenia Gravis Drugs Market Restraints
Table 198. Research Programs/Design for This Report
Table 199. Key Data Information from Secondary Sources
Table 200. Key Data Information from Primary Sources
List of Figures
Figure 1. Myasthenia Gravis Drugs Product Picture
Figure 2. Global Myasthenia Gravis Drugs Sales Market Share by Type in 2021 & 2027
Figure 3. Anticholinesterases Product Picture
Figure 4. Immunosuppressants Product Picture
Figure 5. Intravenous Immune Globulins Product Picture
Figure 6. Global Myasthenia Gravis Drugs Sales Market Share by Application in 2021 & 2027
Figure 7. Hospitals Examples
Figure 8. Clinics Examples
Figure 9. Global Myasthenia Gravis Drugs Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Myasthenia Gravis Drugs Sales Growth Rate (2016-2027) & (US$ Million)
Figure 11. Global Myasthenia Gravis Drugs Sales (K MT) Growth Rate (2016-2027)
Figure 12. Global Myasthenia Gravis Drugs Price Trends Growth Rate (2016-2027) (USD/MT)
Figure 13. Global Myasthenia Gravis Drugs Revenue Market Share by Region: 2016 VS 2021
Figure 14. Global Myasthenia Gravis Drugs Revenue Market Share by Region: 2021 VS 2027
Figure 15. North America Myasthenia Gravis Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 16. North America Myasthenia Gravis Drugs Sales (K MT) Growth Rate (2016-2027)
Figure 17. Europe Myasthenia Gravis Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 18. Europe Myasthenia Gravis Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 19. China Myasthenia Gravis Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. China Myasthenia Gravis Drugs Sales (Million USD) and Growth Rate (2016-2027)
Figure 21. Japan Myasthenia Gravis Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Japan Myasthenia Gravis Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia Myasthenia Gravis Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. Southeast Asia Myasthenia Gravis Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 25. India Myasthenia Gravis Drugs Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. India Myasthenia Gravis Drugs Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Global 5 Largest Myasthenia Gravis Drugs Players Market Share by Revenue in Myasthenia Gravis Drugs: 2016 & 2020
Figure 28. Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 29. Global Myasthenia Gravis Drugs Revenue Share by Type (2016-2021)
Figure 30. Global Myasthenia Gravis Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 31. Global Myasthenia Gravis Drugs Revenue Share by Application (2016-2021)
Figure 32. Global Myasthenia Gravis Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 33. North America Myasthenia Gravis Drugs Sales Market Share by Type in 2020
Figure 34. North America Myasthenia Gravis Drugs Sales Market Share by Application in 2020
Figure 35. Europe Myasthenia Gravis Drugs Sales Market Share by Type in 2020
Figure 36. Europe Myasthenia Gravis Drugs Sales Market Share by Application in 2020
Figure 37. China Myasthenia Gravis Drugs Sales Market Share by Type in 2020
Figure 38. China Myasthenia Gravis Drugs Sales Market Share by Application in 2020
Figure 39. Japan Myasthenia Gravis Drugs Sales Market Share by Type in 2020
Figure 40. Japan Myasthenia Gravis Drugs Sales Market Share by Application in 2020
Figure 41. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Type in 2020
Figure 42. Southeast Asia Myasthenia Gravis Drugs Sales Market Share by Application in 2020
Figure 43. India Myasthenia Gravis Drugs Sales Market Share by Type in 2020
Figure 44. India Myasthenia Gravis Drugs Sales Market Share by Application in 2020
Figure 45. Key Raw Materials Price Trend
Figure 46. Manufacturing Cost Structure of Myasthenia Gravis Drugs
Figure 47. Manufacturing Process Analysis of Myasthenia Gravis Drugs
Figure 48. Myasthenia Gravis Drugs Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed